U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H47N5O6S
Molecular Weight 629.81
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of UPAMOSTAT

SMILES

CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC(=CC=C2)C(\N)=N/O)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C

InChI

InChIKey=HUASEDVYRABWCV-NDEPHWFRSA-N
InChI=1S/C32H47N5O6S/c1-8-43-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34-40)35-44(41,42)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35,40H,8,12-15,17H2,1-7H3,(H2,33,34)/t28-/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H47N5O6S
Molecular Weight 629.81
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Wilex developed WX-UK1 as a specific inhibitor of human trypsin-2, human trypsin-3 and urokinase-plasminogen activator. WX-UK1 participated in phase I clinical trial in combination with capecitabine in advanced malignancies to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics. However, in April 2014, the clinical development of this drug was discontinued, as part of a company restructure.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL3159
Sources: DOI: 10.1158/1535-7163.TARG-17-B055
75.0 nM [Ki]
Target ID: CHEMBL4551
Sources: DOI: 10.1158/1535-7163.TARG-17-B055
19.0 nM [Ki]
Target ID: P00749
Gene ID: 5328.0
Gene Symbol: PLAU
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
2003 Feb
Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
2004 Jul 20
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
2013 Mar 5
Activation of the anti-cancer agent upamostat by the mARC enzyme system.
2013 Sep
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
2015 Mar

Sample Use Guides

Advanced pancreatic adenocarcinoma: 1000 mg m(-2) of gemcitabine IV weekly either alone (arm A) or in combination with 200 mg (arm B) or 400 mg (arm C) oral upamostat daily.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 20:15:39 GMT 2023
Edited
by admin
on Fri Dec 15 20:15:39 GMT 2023
Record UNII
S5M7KW6U17
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
UPAMOSTAT
INN   WHO-DD  
INN  
Official Name English
Upamostat [WHO-DD]
Common Name English
upamostat [INN]
Common Name English
1-PIPERAZINECARBOXYLIC ACID, 4-((2S)-3-(3-((E)-AMINO(HYDROXYIMINO)METHYL)PHENYL)-1-OXO-2-(((2,4,6-TRIS(1-METHYLETHYL)PHENYL)SULFONYL)AMINO)PROPYL)-, ETHYL ESTER
Common Name English
MESUPRON
Brand Name English
WX-671
Code English
ETHYL 4-((2S)-3-(3-((E)-N'-HYDROXYCARBAMIMIDOYL)PHENYL)-2-(2,3,5-TRI(PROPAN-2-YL)BENZENESULFONAMIDO)PROPANOYL)PIPERAZINE-1-CARBOXYLATE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
FDA ORPHAN DRUG 608417
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
Code System Code Type Description
PUBCHEM
9830667
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
INN
9416
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
FDA UNII
S5M7KW6U17
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
EPA CompTox
DTXSID801337307
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
DRUG BANK
DB13052
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
CAS
1191101-18-4
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
WIKIPEDIA
Upamostat
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
SMS_ID
300000021774
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
NCI_THESAURUS
C73985
Created by admin on Fri Dec 15 20:15:39 GMT 2023 , Edited by admin on Fri Dec 15 20:15:39 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY